WO2000075291A3 - Cells with enforced expression of bcl-xl - Google Patents

Cells with enforced expression of bcl-xl Download PDF

Info

Publication number
WO2000075291A3
WO2000075291A3 PCT/EP2000/005195 EP0005195W WO0075291A3 WO 2000075291 A3 WO2000075291 A3 WO 2000075291A3 EP 0005195 W EP0005195 W EP 0005195W WO 0075291 A3 WO0075291 A3 WO 0075291A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
cells
enforced
enforced expression
expression
Prior art date
Application number
PCT/EP2000/005195
Other languages
French (fr)
Other versions
WO2000075291A2 (en
Inventor
Oksana Ivanivna Sirenko
Michael Paul Cooke
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Oksana Ivanivna Sirenko
Michael Paul Cooke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Oksana Ivanivna Sirenko, Michael Paul Cooke filed Critical Novartis Ag
Priority to AU54031/00A priority Critical patent/AU5403100A/en
Publication of WO2000075291A2 publication Critical patent/WO2000075291A2/en
Publication of WO2000075291A3 publication Critical patent/WO2000075291A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to genetically modified CD34+ hematopoietic cells which overexpress a BCL-XL protein, cell populations comprising such cells and their medical uses. The present invention also relates to methods of enforced BCL-XL expression in hematopoietic cells. Such enforced expression results in an increase in hematopoietic cell viability, expansion, and engraftment ability.
PCT/EP2000/005195 1999-06-08 2000-06-06 Cells with enforced expression of bcl-xl WO2000075291A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54031/00A AU5403100A (en) 1999-06-08 2000-06-06 Enforced expression of bcl-xl

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32830899A 1999-06-08 1999-06-08
US09/328,308 1999-06-08

Publications (2)

Publication Number Publication Date
WO2000075291A2 WO2000075291A2 (en) 2000-12-14
WO2000075291A3 true WO2000075291A3 (en) 2001-06-28

Family

ID=23280443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005195 WO2000075291A2 (en) 1999-06-08 2000-06-06 Cells with enforced expression of bcl-xl

Country Status (2)

Country Link
AU (1) AU5403100A (en)
WO (1) WO2000075291A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322618A1 (en) * 2001-07-10 2011-05-18 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
EP1348758A1 (en) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014853A1 (en) * 1994-11-10 1996-05-23 University Of Washington Intrathymic stem cell implantation
WO1996017627A2 (en) * 1994-12-09 1996-06-13 Mosca Joseph D System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014853A1 (en) * 1994-11-10 1996-05-23 University Of Washington Intrathymic stem cell implantation
WO1996017627A2 (en) * 1994-12-09 1996-06-13 Mosca Joseph D System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IMAIZUMI KAZUNORI ET AL: "The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 12, 19 March 1999 (1999-03-19), pages 7975 - 7981, XP002156341, ISSN: 0021-9258 *
KONOPLEVA M ET AL: "Overexpression of antiapoptotic Bcl-XL and Bcl-2 contributes to chemoresistance of quiescent leukemic progenitors and can be selectively reversed by ATRA.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 600A - 601A, XP000971741, ISSN: 0006-4971 *
KONOPLEVA M ET AL: "The antiapoptotic genes BCL-XL and BCL-2 are overexpressed in quiescent leukemic progenitor cells.", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), 39th Annual Meeting of the American Society of Hematology;San Diego, California, USA; December 5-9, 1997, pages 558A, XP000971742, ISSN: 0006-4971 *
MARSHALL WILLIAM L ET AL: "U937 cells overexpressing bcl-xl are resistant to human immunodeficiency virus-1-induced apoptosis and human Immunodeficiency virus-1 replication.", VIROLOGY, vol. 256, no. 1, 30 March 1999 (1999-03-30), pages 1 - 7, XP002156340, ISSN: 0042-6822 *
SANTIAGO-SCHWARZ, FRANCES ET AL: "In vitro expansion of CD13+CD33+ dendritic cell precursors from multipotent progenitors is regulated by a discrete fas-mediated apoptotic schedule", J. LEUKOCYTE BIOL. (1997), 62(4), 493-502, XP000971740 *

Also Published As

Publication number Publication date
AU5403100A (en) 2000-12-28
WO2000075291A2 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
WO2003083070A3 (en) Endothelial cells derived from human embryonic stem cells
WO2004070013A3 (en) Use of islet 1 as a marker for isolating or generating stem cells
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
WO2000006704A3 (en) Hematopoietic cell composition for use in transplantation
WO2000024365A8 (en) Treatment of skin with adenosine or adenosine analog
EP2278022A3 (en) Expression vectors, transfection systems, and method of use thereof
WO2001007568A3 (en) Muscle cells and their use in cardiac repair
CA2390281A1 (en) Hematopoietic differentiation of human embryonic stem cells
DE69734605D1 (en) Weakened salmonella, used as a vechicle for oral immunization
BRPI0417194A (en) stem cells
WO2002077210A3 (en) Methods to culture circovirus
WO2000001231A8 (en) Improved methods for storing neural cells
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
GB9825096D0 (en) Cells,culture methods and their uses
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
WO2004063341A3 (en) Hematopoietic stem cell niche cells
HK1048498A1 (en) Method of proliferating natural killer cells
BR0314402A (en) Ex vivo expansion of root cell populations in mononuclear cell cultures
IL139435A0 (en) Antibodies to dendritic cells and human dendritic cell populations and uses thereof
WO2000075291A3 (en) Cells with enforced expression of bcl-xl
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
WO2004044127A3 (en) Stem cell populations
DE69903559D1 (en) USE OF NEW CELL DEATH INDUCING AGENTS IN SYNERGISM WITH INTERFERON
AU687623B2 (en) Cell Adhesion peptides for use in modifying mutual adhesion among eukaryotic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP